Shots: The approval is based on P-III JAVELIN Bladder 100 study assessing Bavencio (10 mg/kg, IV infusion, q2w) + BSC vs BSC as monothx. in 700 patients with LA/ m-UC […]readmore
Tags : Metastatic Urothelial Carcinoma
Shots: The EMA has validated the type II variation application for Bavencio which is based on P-III JAVELIN Bladder 100 study assessing Bavencio +BSC vs BSC as monothx. in 700 […]readmore
Shots: The companies have completed the submission of sBLA to the US FDA as 1L maintenance therapy for patients with LA/m-UC and have received FDA’s BT designation for the same […]readmore
Shots: The P-III JAVELIN Bladder 100 study involves assessing of Bavencio + best supportive care (BSC) vs BSC monothx in 700 patients with LA or mUC whose disease did not […]readmore
Shots: The P-1b/2 KEYNOTE-146/Study 111 trial involves assessing of Lenvima (20 mg/day) + Keytruda (200 mg IV q3w) in patients with NSCLC, Advanced melanoma & urothelial cancer P1b/2 KEYNOTE-146/Study 111 […]readmore